Cullen Frost Bankers Inc. Acquires 1,081 Shares of ADMA Biologics Inc $ADMA

Cullen Frost Bankers Inc. lifted its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 112.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,042 shares of the biotechnology company’s stock after purchasing an additional 1,081 shares during the period. Cullen Frost Bankers Inc.’s holdings in ADMA Biologics were worth $37,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Nuveen LLC bought a new stake in ADMA Biologics during the 1st quarter worth approximately $93,543,000. Vaughan Nelson Investment Management L.P. bought a new stake in ADMA Biologics during the 2nd quarter worth approximately $32,786,000. Driehaus Capital Management LLC raised its stake in ADMA Biologics by 114.9% during the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after acquiring an additional 1,575,363 shares during the period. Invesco Ltd. raised its stake in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock worth $255,279,000 after acquiring an additional 1,570,649 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in ADMA Biologics by 152.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company’s stock worth $32,392,000 after acquiring an additional 986,666 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $27.67.

ADMA Biologics Trading Down 0.5%

ADMA Biologics stock opened at $15.18 on Monday. The stock has a market cap of $3.62 billion, a P/E ratio of 17.65 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The firm’s 50 day moving average price is $15.81 and its 200-day moving average price is $18.24.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to analysts’ expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.13 earnings per share. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.